FDA Approves ThromboGenics Product Jetrea for Treating Eye Condition

The Food and Drug Administration Oct. 18 announced it has approved Jetrea (ocriplasmin), the first drug approved to treat an eye condition called symptomatic vitreomacular adhesion (VMA).

VMA can contribute to eye problems if the vitreous (jelly in the center of the eye) starts to move away from the macula (a part of the retina responsible for reading vision), the agency said. This movement can lead to damage of the macula due to pulling or tugging on the macula.

Jetrea, which is manufactured by Belguim-based ThromboGenics NV, is an enzyme that breaks down proteins in the eye responsible for VMA, ...